Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment

Documenti analoghi

• Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
  di: Soria, Francesco, et al.
  Pubblicazione: (2018)
• Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
  di: Adashek, Jacob J., et al.
  Pubblicazione: (2019)
• Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
  di: Shen, Pan, et al.
  Pubblicazione: (2021)
• Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
  di: Onesti, Concetta Elisa, et al.
  Pubblicazione: (2018)
• Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
  di: Zang, Hongjing, et al.
  Pubblicazione: (2020)